Levamisole/5-fluorouracil for colon cancer
Drug combo has been shown to substantially reduce cancer recurrence rates, delay onset of tumor relapse and improve survival rates for patients following surgical treatment, according to study of 408 patients released by NCI Oct. 2. Treatment IND for combo was approved in May. 48% of patients treated with combo were alive five years after therapy compared to 37% who received no post-operative treatment. Study's principal investigator concluded that "the option of therapy with levamisole and 5-FU should be offered to almost all patients who have surgical treatment for high-risk, stage C [Duke's] colon cancer".
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
INFOGRAPHIC: An interactive timeline of selected HBW Insight coverage of the growing European CBD dietary supplements market in 2020. The timeline covers the main events of a rollercoaster 12 months, including the European Commission’s indecision on whether to classify CBD as narcotic or novel food and how the path forward became clear in the UK.
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.